388 related articles for article (PubMed ID: 17552110)
41. Long-term use of daptomycin for MRSA osteomyelitis and joint infection.
Burns CA
Scand J Infect Dis; 2008; 40(2):183-6. PubMed ID: 17852899
[TBL] [Abstract][Full Text] [Related]
42. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
Twilla JD; Gelfand MS; Cleveland KO; Usery JB
J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
[No Abstract] [Full Text] [Related]
43. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
[TBL] [Abstract][Full Text] [Related]
44. Methicillin-resistant Staphylococcus aureus infection with intermediate sensitivity to vancomycin: a case report and literature review.
Schairer J; Sankri-Tarbichi AG; Fairfax MR; Salimnia H; Guzman JA
J Intensive Care Med; 2008; 23(5):338-41. PubMed ID: 18701528
[TBL] [Abstract][Full Text] [Related]
45. Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.
Katz DE; Martone WJ
Clin Ther; 2007 Nov; 29(11):2440-7. PubMed ID: 18158084
[TBL] [Abstract][Full Text] [Related]
46. Detection of an outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital.
Mallaval FO; Carricajo A; Delavenna F; Recule C; Fonsale N; Manquat G; Raffenot D; Rogeaux O; Aubert G; Tous J
Clin Microbiol Infect; 2004 May; 10(5):459-61. PubMed ID: 15113326
[TBL] [Abstract][Full Text] [Related]
47. Postpartum iliopsoas pyomyositis due to community-acquired methicillin-resistant Staphylococcus aureus.
Sokolov KM; Kreye E; Miller LG; Choi C; Tang AW
Obstet Gynecol; 2007 Aug; 110(2 Pt 2):535-8. PubMed ID: 17666656
[TBL] [Abstract][Full Text] [Related]
48. Key considerations in the treatment of complicated staphylococcal infections.
Jones RN
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
[TBL] [Abstract][Full Text] [Related]
49. Update on emerging infections: news from the Centers for Disease Control and Prevention.
Moran GJ; Mount J
Ann Emerg Med; 2003 Jan; 41(1):148-51. PubMed ID: 12514697
[No Abstract] [Full Text] [Related]
50. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
51. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Leonard SN; Cheung CM; Rybak MJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2974-6. PubMed ID: 18519721
[TBL] [Abstract][Full Text] [Related]
52. Prospective comparison of methicillin-susceptible and methicillin-resistant community-associated Staphylococcus aureus infections in hospitalized patients.
Skiest DJ; Brown K; Cooper TW; Hoffman-Roberts H; Mussa HR; Elliott AC
J Infect; 2007 May; 54(5):427-34. PubMed ID: 17070598
[TBL] [Abstract][Full Text] [Related]
53. [Methicillin-resistant Staphylococcus aureus (MRSA) in the community].
Vonk AG; Vandenbroucke-Grauls CM
Ned Tijdschr Geneeskd; 2007 Feb; 151(7):401-7. PubMed ID: 17343138
[TBL] [Abstract][Full Text] [Related]
54. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus.
Appelbaum PC
Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():16-23. PubMed ID: 16445720
[TBL] [Abstract][Full Text] [Related]
55. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals.
Cartolano GL; Cheron M; Benabid D; Leneveu M; Boisivon A;
Clin Microbiol Infect; 2004 May; 10(5):448-51. PubMed ID: 15113324
[TBL] [Abstract][Full Text] [Related]
56. Beyond MRSA: the growing menace of hVISA and VISA.
Bulchandani D; Nachnani J; Fitzsimmons C; Jost P; Brewer J
South Med J; 2008 Jun; 101(6):663-4. PubMed ID: 18528225
[No Abstract] [Full Text] [Related]
57. Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative.
Bobin-Dubreux S; Reverdy ME; Nervi C; Rougier M; Bolmström A; Vandenesch F; Etienne J
Antimicrob Agents Chemother; 2001 Jan; 45(1):349-52. PubMed ID: 11120996
[TBL] [Abstract][Full Text] [Related]
58. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
Moise PA; North D; Steenbergen JN; Sakoulas G
Lancet Infect Dis; 2009 Oct; 9(10):617-24. PubMed ID: 19778764
[TBL] [Abstract][Full Text] [Related]
59. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11 year period.
Sancak B; Yagci S; Mirza HC; Hasçelik G
J Antimicrob Chemother; 2013 Nov; 68(11):2689-91. PubMed ID: 23788481
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
